Analysts' Actions: AIG, DOW, EZPW, FOSL

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Aetna ( AET) was downgraded from Neutral to Sell at Goldman Sachs. Commercial margins could continue to fall, Goldman said. $45 price target.

AIG ( AIG) was upgraded to Buy at Goldman Sachs. Chart is is showing progress, and the company has multiple potential catalysts, Goldman said. $40 price target.

CF Industries ( CF) was downgraded at Dahlman Rose. Higher corn supplies could weigh on prices, Dahlman Rose said. $155 price target.

Dish ( DISH) was downgraded to Hold at TheStreet Ratings.

Dow Chemical ( DOW) was upgraded at Morgan Stanley from Equal-Weight to Overweight. $38 price target. Company should benefit from lower ethane prices, Morgan Stanley said.

EZCorp ( EZPW) was upgraded at Sterne Agee from Underperform to Neutral. Valuation call, based on a $24 price target, Sterne Agee said.

Fossil ( FOSL) was upgraded at Benchmark from Hold to Buy. $100 price target. Estimates also cut, given lower expected sales in Europe, Benchmark said.

Fossil was downgraded at JP Morgan from Overweight to Neutral. Company's growth story is in transition, JP Morgan said. $88 price target.

Generac Holdings ( GNRC) was downgraded at Goldman Sachs to Neutral from Buy. $30 price target. Risk reward around consensus estimates is now balanced, Goldman said.

Global Partners ( GLP) was downgraded to Hold at TheStreet Ratings.

Herbalife ( NOK) was downgraded at Caris & Co. from Buy to Average. $39 price target. Expect David Einhorn to weigh on sentiment, Caris said.

Hershey ( HSY) was upgraded at Argus from Hold to Buy. $78 price target. Company is realizing higher sales growth, Argus said.

Humana ( HUM) was downgraded at Goldman Sachs from Buy to Neutral. Valuation call, based on a $90 price target, Goldman said.

Immunomedics ( IMMU) was downgraded to Hold at TheStreet Ratings.

Jive Software ( JIVE) was initiated with a Hold rating at Needham. Valuation call, Needham said.

Janus Capital ( JNS) was upgraded at Bank of America/Merrill Lynch from Underperform to Neutral. Valuation call, based on an $8.50 price target, Bank of America/Merrill Lynch said.

Magellan Health Services ( MGLN) was upgraded at Bank of America/Merrill to Buy from Underperform. $52 price target. Big contract extension derisks outlook, BofA/Merrill said.

Phillips 66 ( PSX) was initiated with an Outperform rating at Credit Suisse. $42 price target. Company can deliver above-average growth, Credit Suisse said.

Scotts Miracle Gro ( SMG) was upgraded at BMO Capital Markets to Market Perform from Underperform. $42 price target. Stock fell 16% on earnings, BMO Capital Markets said.

St. Jude ( STJ) was upgraded at Morgan Stanley from Equal-Weight to Overweight. $52 price target. Company is leveraged to growth in new cardio markets and can expand margins, Morgan Stanley said.

Under Armour ( UA) was initiated with a Buy rating at Benchmark. $104 price target. Stock is attractively valued, following a recent pullback, Benchmark said.

Veeco Instruments ( VECO) was upgraded at Piper Jaffray from Neutral to Overweight. $50 price target. Company is positioned well for the next upcycle, Piper Jaffray said.

Zynga ( ZNGA) was initiated with a Buy rating at Citigroup. $12 price target. Attractive valuation with room to grow, Citi said.

STOCK COMMENTS / EPS CHANGES

Amedisys ( AMED) numbers were lowered at Jefferies. Shares are now seen reaching $15. Estimates were also lowered on reimbursement uncertainty, Jefferies said. Hold rating.

Franklin Resources ( BEN) numbers were reduced at BMO Capital. Estimates were cut through 2013. Market pullback is weighing on assets, BMO said. Market Perform rating and new $133 price target.

Buckeye Partners ( BPL) numbers were cut at UBS. Shares are now seen reaching $64. Estimates were also trimmed on broad weakness that dragged down the first quarter, UBS said. Buy rating.

Walt Disney ( DIS) numbers were raised at Credit Suisse. Shares are now seen reaching $50. Estimates were also increased, given higher growth in cable, parks and broadcasting, Credit Suisse said. Outperform rating.

Dollar Tree ( DLTR) numbers were boosted at BMO Capital. Shares are now seen reaching $117. Estimates were also boosted, given higher expected comp sales growth, BMO Capital said. Outperform rating.

Generac numbers were raised at Oppenheimer. Shares are now seen reaching $34. Estimates were also raised on robust first quarter, Oppenheimer said. Outperform rating.

Huntington Bancshares ( HBAN) numbers were raised at Bank of America/Merrill Lynch. Estimates were raised through 2013. Company should see lower credit losses, BofA/Merrill said. Buy rating and new $7.25 price target.

Hartford Financial Group ( HIG) numbers were lowered at UBS. Shares are now seen reaching $33. Estimates were also lowered as recent actions are good, but management must execute, UBS said. Buy rating.

NetApp ( NTAP) estimates, price target were reduced at BMO Capital. Shares are now seen reaching $45. Estimates were also cut, as EMC ( EMC) appears to be gaining market share with aggressive pricing. Outperform rating.

Transdigm ( NTAP) estimates, price target were increased at Credit Suisse. Estimates were raised through 2014. Acquisitions are adding to growth, and the company is seeing solid pricing, Credit Suisse said. Outperform rating and new $151 price target.

Tempur-Pedic ( TPX) price target was lowered at Oppenheimer to $75. Substantial drop in shares, Oppenheimer said. Outperform rating.

Vitamin Shoppe ( VSI) numbers were increased at BMO Capital. Estimates were raised through 2013. Comp sales growth is accelerating, BMO said. Market Perform rating and new $55 price target.

Wendy's ( WEN) estimates, price target were reduced at BMO Capital. Shares are now seen reaching $5. Estimates were also cut, given the company's new guidance, BMO Capital said. Market Perform rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.